Search | National Quality Measures Clearinghouse | “Neoplasms”

Search | National Quality Measures Clearinghouse

• MEASURE SUMMARY
 
• NQMC:007191
 
• 2009 NOV

Melanoma: percentage of patients with a melanoma less than or equal to 1 mm thick (i.e., T1) for whom the surgical excision margins are 1 cm (or the specific anatomic or cosmetic factors that limit margin distance are noted).

American College of Surgeons

Compare

• MEASURE SUMMARY
 
• NQMC:007211
 
• 2009 NOV

Melanoma: percentage of patients with melanoma who have biopsy-proven, palpable nodal disease who do not undergo sentinel lymph node biopsy (SLNB).

American College of Surgeons

Compare

• MEASURE SUMMARY
 
• NQMC:007188
 
• 2009 NOV

Melanoma: percentage of patients with a melanoma in situ (i.e., Tis) for whom the surgical excision margins are 5 mm (or the specific anatomic or cosmetic factors that limit margin distance are noted).

American College of Surgeons

Compare

• MEASURE SUMMARY
 
• NQMC:007194
 
• 2009 NOV

Melanoma: percentage of patients to undergo a sentinel lymph node biopsy (SLNB) for melanoma for whom lymphoscintigraphy is performed to identify the draining nodal basin(s) when drainage to more than one basin is possible.

American College of Surgeons

Compare

• MEASURE SUMMARY
 
• NQMC:007200
 
• 2009 NOV

Melanoma: percentage of patients who undergo an axillary lymph node dissection (LND) or completion lymph node dissection (CLND) for melanoma for whom at least 10 regional lymph nodes are resected and pathologically examined.

American College of Surgeons

Compare

• MEASURE SUMMARY
 
• NQMC:007197
 
• 2009 NOV

Melanoma: percentage of patients who have a stage Ib or II melanoma with whom sentinel lymph node biopsy (SLNB) is discussed.

American College of Surgeons

Compare

• MEASURE SUMMARY
 
• NQMC:007206
 
• 2009 NOV

Melanoma: percentage of patients who have a resected primary melanoma metastatic to regional lymph nodes or distant sites for whom there is a documented discussion regarding adjuvant therapy.

American College of Surgeons

Compare

• MEASURE SUMMARY
 
• NQMC:007189
 
• 2009 NOV

Melanoma: percentage of patients with a melanoma for whom the surgeon documented the measured surgical margin in the operative report.

American College of Surgeons

Compare

• MEASURE SUMMARY
 
• NQMC:007209
 
• 2009 NOV

Melanoma: percentage of patients with melanoma having biopsy-proven or palpable nodal disease and no evidence of distant metastases who undergo a lymph node dissection (LND).

American College of Surgeons

Compare

• MEASURE SUMMARY
 
• NQMC:008657
 
• 2012 NOV
• NQF-ENDORSED MEASURE

Melanoma: percentage of patients, regardless of age, with a current diagnosis of melanoma or a history of melanoma whose information was entered, at least once within the 12 month period, into a recall system.[Update Pending]

American Academy of Dermatology; National Committee for Quality Assurance; Physician Consortium for Performance Improvement®

Compare

• MEASURE SUMMARY
 
• NQMC:011011
 
• 2016 NOV

Melanoma: percentage of patient visits, regardless of age, with a new occurrence of melanoma that have a treatment plan documented in the chart that was communicated to the physician(s) providing continuing care within one month of diagnosis.

American Academy of Dermatology; National Committee for Quality Assurance; Physician Consortium for Performance Improvement®

Compare

• MEASURE SUMMARY
 
• NQMC:007195
 
• 2009 NOV

Melanoma: percentage of patients who undergo a sentinel lymph node biopsy (SLNB) for melanoma for whom the sentinel lymph nodes (SLNs) are sent for permanent sectioning only (no frozen sections), unless a reason is documented.

American College of Surgeons

Compare

• MEASURE SUMMARY
 
• NQMC:007204
 
• 2009 NOV

Melanoma: percentage of patients who undergo a sentinel lymph node biopsy (SLNB) or lymph node dissection (LND) for melanoma for whom the pathology report documents the number of lymph nodes examined and the number of lymph nodes found to contain metastases.

American College of Surgeons

Compare

• MEASURE SUMMARY
 
• NQMC:007192
 
• 2009 NOV

Melanoma: percentage of patients with a melanoma 1-2 mm thick (i.e., T2) for whom the surgical excision margins are 1-2 cm (or the specific anatomic or cosmetic factors that limit margin distance are noted).

American College of Surgeons

Compare

• MEASURE SUMMARY
 
• NQMC:007212
 
• 2009 NOV

Melanoma: percentage of patients treated for melanoma for whom stage-specific follow-up, including future skin exams, is discussed and documented.

American College of Surgeons

Compare

• EXPERT COMMENTARY
 

Importance of Quality Metrics for Providing High Quality Melanoma Care

By: Karl Y. Bilimoria, MD, MS

• MEASURE SUMMARY
 
• NQMC:007201
 
• 2009 NOV

Melanoma: percentage of patients who undergo an inguinal lymph node dissection (LND) or completion lymph node dissection (CLND) for melanoma for whom at least five regional lymph nodes are resected and pathologically examined.

American College of Surgeons

Compare

• MEASURE SUMMARY
 
• NQMC:007198
 
• 2009 NOV

Melanoma: percentage of patients with melanoma and clinically apparent/palpable lymphadenopathy for whom a lymph node dissection (LND) is performed without an antecedent histologic diagnosis.

American College of Surgeons

Compare

• MEASURE SUMMARY
 
• NQMC:007187
 
• 2009 NOV

Melanoma: is the surgeon who performs sentinel lymph node biopsy (SLNB) or lymph node dissection (LND) for melanoma certified by the American Board of Surgery or equivalent board or international association?

American College of Surgeons

Compare

• MEASURE SUMMARY
 
• NQMC:007207
 
• 2009 NOV

Melanoma: percentage of patients who have stages 0, I, or IIA melanoma for whom an abdominal CT/MRI, pelvic CT/MRI, or PET scan was not performed, except in response to specific signs or symptoms.

American College of Surgeons